Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 1Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 20Carcinoma, Non-Small-Cell Lung 19Pancreatic Neoplasms 17Triple Negative Breast Neoplasms 16Neoplasm Metastasis 9Parkinson Disease 4, Autosomal Dominant Lewy Body 6Neoplasms 5Lung Neoplasms 4Carcinoma 4Neoplasms by Site 3Adenocarcinoma 3Pancreatic Diseases 2Ovarian Neoplasms 2Neoplasms by Histologic Type 2Fallopian Tube Neoplasms 2Endocrine System Diseases 2Endocrine Gland Neoplasms 2Digestive System Neoplasms 2Digestive System Diseases 2Carcinoma, Pancreatic Ductal 2Carcinoma, Ductal, Breast 2Vaccinia 1Thromboembolism 1Thoracic Neoplasms 1Squamous Non-Small Cell Lung Cancer 1Squamous Cell Carcinoma of Head and Neck 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Peritoneal Neoplasms 1Pancreatic cancer, adult 1

Interventions

Carboplatin 8Paclitaxel 7Hyperthermic Intraperitoneal Chemotherapy 7Bevacizumab 4liposomal doxorubicin 3Gemcitabine 3Oxaliplatin 2Neoadjuvant Therapy 2relacorilant 1phenoxodiol 1pembrolizumab 1oregovomab 1olaparib 1nintedanib 1lobaplatin 1lanreotide 1epothilone B 1atezolizumab 1Trabectedin 1Topotecan 1Therapeutics 1Surgical Procedures, Operative 1Saline Solution 1Leucovorin 1Letrozole 1Laparotomy 1Laparoscopy 1LAIF 900 1Hypericum extract LI 160 1Glucose 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Peritoneal Neoplasms × 130-nm albumin-bound paclitaxel × Clear all
NCT05257408 2025-04-16

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

Corcept Therapeutics

Phase 3 Active not recruiting
381 enrolled 1 FDA
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡